Alembic Pharmaceuticals Limited (APLLTD.BO)
INR 1045.0
(-1.04%)
INR 1045.0
(-1.04%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 61.12 Billion INR | 13.25% |
| 2022 | 54.99 Billion INR | 5.12% |
| 2021 | 52.31 Billion INR | -0.84% |
| 2020 | 52.76 Billion INR | 17.46% |
| 2019 | 44.91 Billion INR | 18.0% |
| 2018 | 38.06 Billion INR | 25.42% |
| 2017 | 30.35 Billion INR | 0.16% |
| 2016 | 30.3 Billion INR | -0.2% |
| 2015 | 30.36 Billion INR | 51.06% |
| 2014 | 20.09 Billion INR | 10.43% |
| 2013 | 18.2 Billion INR | 21.9% |
| 2012 | 14.93 Billion INR | 4.22% |
| 2011 | 14.32 Billion INR | 19.19% |
| 2010 | 12.02 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 15.61 Billion INR | 2.95% |
| 2023 Q2 | 15.94 Billion INR | 7.32% |
| 2023 FY | 62.28 Billion INR | 13.25% |
| 2023 Q1 | 14.86 Billion INR | 18.55% |
| 2023 Q3 | 16.3 Billion INR | 2.23% |
| 2023 Q4 | 15.16 Billion INR | -6.97% |
| 2022 Q2 | 14.75 Billion INR | 16.87% |
| 2022 FY | 54.99 Billion INR | 5.12% |
| 2022 Q3 | 15.09 Billion INR | 2.31% |
| 2022 Q4 | 12.53 Billion INR | -16.93% |
| 2022 Q1 | 12.62 Billion INR | -5.93% |
| 2021 FY | 52.31 Billion INR | -0.84% |
| 2021 Q2 | 12.92 Billion INR | -2.54% |
| 2021 Q1 | 13.26 Billion INR | 13.97% |
| 2021 Q3 | 12.71 Billion INR | -1.6% |
| 2021 Q4 | 13.41 Billion INR | 5.51% |
| 2020 FY | 52.76 Billion INR | 17.46% |
| 2020 Q4 | 11.63 Billion INR | -11.48% |
| 2020 Q3 | 13.14 Billion INR | -9.8% |
| 2020 Q2 | 14.57 Billion INR | 8.63% |
| 2020 Q1 | 13.41 Billion INR | 22.71% |
| 2019 Q1 | 9.48 Billion INR | 18.78% |
| 2019 FY | 44.91 Billion INR | 18.0% |
| 2019 Q4 | 10.93 Billion INR | -9.6% |
| 2019 Q2 | 12.4 Billion INR | 30.77% |
| 2019 Q3 | 12.09 Billion INR | -2.56% |
| 2018 Q4 | 7.98 Billion INR | -21.54% |
| 2018 Q1 | 8.62 Billion INR | 1.08% |
| 2018 Q2 | 11.27 Billion INR | 30.67% |
| 2018 Q3 | 10.18 Billion INR | -9.66% |
| 2018 FY | 38.06 Billion INR | 25.42% |
| 2017 Q2 | 7.89 Billion INR | 21.77% |
| 2017 FY | 30.35 Billion INR | 0.16% |
| 2017 Q4 | 8.53 Billion INR | 1.58% |
| 2017 Q3 | 8.4 Billion INR | 6.43% |
| 2017 Q1 | 6.48 Billion INR | -12.57% |
| 2016 Q1 | 7.36 Billion INR | 19.02% |
| 2016 FY | 30.3 Billion INR | -0.2% |
| 2016 Q3 | 7.77 Billion INR | -11.64% |
| 2016 Q4 | 7.41 Billion INR | -4.59% |
| 2016 Q2 | 8.79 Billion INR | 19.36% |
| 2015 Q3 | 9.15 Billion INR | -8.76% |
| 2015 Q1 | 5.81 Billion INR | 24.78% |
| 2015 Q4 | 6.19 Billion INR | -32.37% |
| 2015 FY | 30.36 Billion INR | 51.06% |
| 2015 Q2 | 10.03 Billion INR | 72.51% |
| 2014 Q4 | 4.66 Billion INR | -8.77% |
| 2014 Q3 | 5.1 Billion INR | -6.46% |
| 2014 Q2 | 5.46 Billion INR | 11.0% |
| 2014 Q1 | 4.92 Billion INR | 15.42% |
| 2014 FY | 20.09 Billion INR | 10.43% |
| 2013 Q2 | 4.83 Billion INR | 13.63% |
| 2013 Q1 | 4.25 Billion INR | 20.8% |
| 2013 Q3 | 4.84 Billion INR | 0.06% |
| 2013 FY | 18.2 Billion INR | 21.9% |
| 2013 Q4 | 4.26 Billion INR | -11.93% |
| 2012 FY | 14.93 Billion INR | 4.22% |
| 2012 Q3 | 3.71 Billion INR | -8.11% |
| 2012 Q4 | 3.52 Billion INR | -5.2% |
| 2012 Q1 | 3.64 Billion INR | 0.0% |
| 2012 Q2 | 4.04 Billion INR | 10.88% |
| 2011 FY | 14.32 Billion INR | 19.19% |
| 2010 FY | 12.02 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Ajanta Pharma Limited | 42.08 Billion INR | -45.225% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -1351.013% |
| Sigachi Industries Limited | 3.98 Billion INR | -1432.026% |
| Bal Pharma Limited | 3.39 Billion INR | -1701.815% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | -377.173% |
| Medico Remedies Limited | 1.44 Billion INR | -4117.555% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -5758.159% |
| Venus Remedies Limited | 5.91 Billion INR | -933.412% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -7990.656% |
| Alpa Laboratories Limited | 1.08 Billion INR | -5520.9% |
| Nectar Lifesciences Limited | 16.84 Billion INR | -262.933% |
| Shilpa Medicare Limited | 11.51 Billion INR | -430.748% |
| Aarti Drugs Limited | 25.28 Billion INR | -141.721% |
| Lupin Limited | 200.1 Billion INR | 69.456% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 78.707% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 67.867% |
| Windlas Biotech Limited | 6.3 Billion INR | -868.706% |
| Suven Life Sciences Limited | 116.92 Million INR | -52171.977% |
| Eris Lifesciences Limited | 20.09 Billion INR | -204.215% |
| Valiant Laboratories Limited | 1.82 Billion INR | -3257.247% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | -75.424% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | -393.553% |
| Ipca Laboratories Limited | 76.22 Billion INR | 19.814% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -693.528% |
| Achyut Healthcare Limited | 61.36 Million INR | -99496.05% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 87.397% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -1191.06% |
| RPG Life Sciences Limited | 5.82 Billion INR | -950.101% |
| Mankind Pharma Limited | 103.34 Billion INR | 40.859% |
| Laurus Labs Limited | 50.01 Billion INR | -22.198% |
| Piramal Pharma Limited | 81.71 Billion INR | 25.199% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -2257.667% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 42.368% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 48.26% |
| Unichem Laboratories Limited | 16.57 Billion INR | -268.773% |
| Sequent Scientific Limited | 13.69 Billion INR | -346.227% |
| Novartis India Limited | 3.35 Billion INR | -1724.129% |
| Wanbury Limited | 5.75 Billion INR | -961.776% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -481.356% |
| Wockhardt Limited | 27.89 Billion INR | -119.151% |
| Themis Medicare Limited | 3.81 Billion INR | -1501.031% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -2828.63% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 8.814% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | -167.698% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 78.106% |
| Divi's Laboratories Limited | 78.45 Billion INR | 22.089% |
| NATCO Pharma Limited | 40.02 Billion INR | -52.726% |
| Gufic Biosciences Limited | 8.06 Billion INR | -657.7% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | -188.449% |
| Ind-Swift Limited | 5.02 Billion INR | -1116.418% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -430.906% |
| FDC Limited | 19.42 Billion INR | -214.58% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -12022.031% |
| Granules India Limited | 45.06 Billion INR | -35.633% |
| Medicamen Biotech Limited | 1.79 Billion INR | -3308.756% |
| Alkem Laboratories Limited | 126.67 Billion INR | 51.75% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | -371.785% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -15166.802% |
| Brooks Laboratories Limited | 794.86 Million INR | -7589.533% |
| Megasoft Limited | 373.95 Million INR | -16244.594% |
| ZIM Laboratories Limited | 3.67 Billion INR | -1563.501% |
| Strides Pharma Science Limited | 40.51 Billion INR | -50.874% |
| Neuland Laboratories Limited | 15.58 Billion INR | -292.159% |
| Morepen Laboratories Limited | 17.01 Billion INR | -259.135% |
| Hikal Limited | 17.84 Billion INR | -242.492% |
| Indoco Remedies Limited | 17.89 Billion INR | -241.564% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | -236.662% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -3859.326% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -1558.219% |
| Hester Biosciences Limited | 3.04 Billion INR | -1906.958% |